FDA's Gottlieb blames industry 'Kabuki drug pricing' for high costs

WASHINGTON (Reuters) - U.S. Food and Drug Administration chief Scott Gottlieb on Wednesday criticized drugmakers, pharmacy benefit managers and health insurers for "Kabuki drug-pricing constructs" that expose consumers to high costs and that discourage competition.